Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 601–700 of 1,001
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“More importantly, anti-obesity medications are recommended as adjunctive tools, whereas lifestyle interventions remain the cornerstone of obesity management and prevention 151,152 .”
Hurtado, M. D., Tama, E., D’Andre, S., & SHUFELT, C. L. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104213 · Cited by 12
Soslu, R., Uysal, A., DEVRİLMEZ, M., Çuvalcıoğlu, İ. C., Doğan, A. A., Karaburgu, S., & Taş, M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1219780 · Cited by 16
Tian, Y., Li, F., Du, L., Zhang, L., Yang, Z., Yu, T., Ma, X., Wang, Y., Wang, A., Peng, D., et al. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106072 · Cited by 13
Impact of non-sugar sweeteners on metabolism beyond sweet taste perception
Herzog, H., Zhang, L., Fontana, L., & Neely, G. G. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.10.008 · Cited by 16
Gupta, N., Babyak, A., Chorbajian, A., Tardio, V., Ballreich, J. M., & Dasgupta, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16627 · Cited by 11
López-Jiménez, F. A., Cesare, M. D., Powis, J., Shrikhande, S. S., Adeoye, M., Codato, E., Zhou, B., Bixby, H., Evans, N. R., Lara-Breitinger, K. M., et al. (2025) · Global Heart · doi:10.5334/gh.1451 · Cited by 19
Clinical impact of visceral-to-subcutaneous fat ratio in patients with acute aortic dissection
Miura, Y., Higuchi, S., Matsushita, K., Kariyasu, T., Machida, H., Yokoyama, K., Soejima, K., & Satoh, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226642 · Cited by 10
“If increased VFA and VS ratios are found to be associated with, or responsible for, subsequent adverse events, these variables could be utilized to predict adverse events or as targets for lifestyle including diet and aerobic exercise [18, 19], pharmacological [20], and surgical [21] interventions.”
BackgroundAbdik, H., Cumbul, A., Hayal, T. B., Abdik, E. A., Taşlı, P. N., Kırbaş, O. K., Baban, D., & Şahin, F. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126736 · Cited by 9
Role of CD38 in Adipose Tissue: Tuning Coenzyme Availability?
Benzi, A., Grozio, A., Spinelli, S., Sturla, L., Guse, A. H., FLORA, A. D., Zocchi, E., Heeren, J., & Bruzzone, S. (2021) · Nutrients · doi:10.3390/nu13113734 · Cited by 10
“major public health emergencies in developed societies, often associated with metabolic complications including dyslipidemia, insulin resistance, type 2 diabetes, fatty liver disease, cardiovascular disease, and cancer [32].”
BackgroundHuang, M., Rodrigues, C. D. S. C., Waitzberg, D. L., da Rocha, I. M. G., & Curioni, C. C. (2023) · Nutrients · doi:10.3390/nu15092203 · Cited by 11
“thermogenesis, inhibiting pancreatic lipase activity, reducing food intake, reducing fat absorption, increasing lipolysis and decreasing lipogenesis [4].”
BackgroundResultEthnic and Racial Disparities in the Behavioral, Pharmacologic, and Surgical Treatment of Obesity
Apovian, C. M., & Istfan, N. W. (2016) · Endocrine Practice · doi:10.4158/ep161531.co · Cited by 12
Self-citationPharmacotherapy in Treatment of Obesity
Keith, J. N. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.07.011 · Cited by 11
Grammatikopoulou, M. G., Chourdakis, M., Gkiouras, K., Roumeli, P., Poulimeneas, D., Apostolidou, E., Chountalas, I., Tirodimos, I., Filippou, O., Papadakou-Lagogianni, S., et al. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0821-9 · Cited by 13
“During the last years, the inflating prevalence of pediatric obesity throughout the world is increasing the demand for obesity-educated health practitioners [1].”
BackgroundEfficacy of chalcone and xanthine derivatives on lipase inhibition: A systematic review
Tam, D. N. H., Mostafa, E. M., Tu, V. L., Rashidy, A. I., Matenoglou, E., Kassem, M. A. M., Soa, D. T., Bayumi, A., Emam, H. E., Tran, L., et al. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13626 · Cited by 11
“In addition to the behavioral modifications such as diet and exercise, pharmacotherapy is also considered for obesity treatment with overweight patients who have a body mass index (BMI) ≥30 or ≥27 kg/m2 with comorbidity (Apovian et al., 2015).”
BackgroundCombining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies
Kahan, S., Saunders, K. H., & Kaplan, L. M. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.05.002 · Cited by 10
Comprehensive Obesity Education for Family Medicine Residents
Khandalavala, B. N., Koran-Scholl, J. B., & Geske, J. (2020) · PRiMER · doi:10.22454/primer.2020.525629 · Cited by 11
Weight Cycling in Women: Adaptation or Risk?
Carey, K. J., & Vitek, W. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0040-1721418 · Cited by 13
Obesity Primer for the Practicing Gastroenterologist
Jirapinyo, P., & Thompson, C. C. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001200 · Cited by 12
“If the response is deemed ineffective (,5% TWL at 3 months) or if safety or intolerability issue arises, the medication should be discontinued and switched to an alternative medication or treatment approach (26).”
BackgroundTools for Successful Weight Management in Primary Care
Turer, C. B., & Palmer, B. F. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000530 · Cited by 12
“Actively reviewing and managing medications that affect weight is an important part of weight management; however, off-label use of medications approved for other indications solely for the purpose of weight loss is not recommended.(36) The 2013 Guidelines for the Management of Overweight and Obesity in Adults outline…”
BackgroundManaging comorbid obesity and depression through clinical pharmacotherapies
McElroy, S. L., Guerdjikova, A. I., Mori, N. N., & Keck, P. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1198776 · Cited by 11
“A growing number of weight-loss drugs are available for the management of persons with obesity (see Table 2) [88,89].”
BackgroundRole of Sex and the Environment in Moderating Weight Gain Due to Inadequate Sleep
Coborn, J. E., Houser, M. M., Perez‐Leighton, C. E., & Teske, J. A. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0290-7 · Cited by 11
Ferreira‐Hermosillo, A., Molina-Ayala, M., Molina-Guerrero, D., Garrido-Mendoza, A. P., Ramírez‐Rentería, C., Mendoza‐Zubieta, V., Espinosa-Cárdenas, E., & Mercado, M. (2020) · Trials · doi:10.1186/s13063-020-4121-x · Cited by 15
Anti-Obesity Effects of a Prunus persica and Nelumbo nucifera Mixture in Mice Fed a High-Fat Diet
Song, J., Kim, J., Park, H., & Kim, H. (2020) · Nutrients · doi:10.3390/nu12113392 · Cited by 14
“These drugs are approved for moderately or severely obese patients with a body mass index (BMI) ≥30 or BMI ≥27 with comorbidities and have a high incidence of side effects [4].”
BackgroundFuller, T., Newberry, Z., Nasir, M., & Tondt, J. (2024) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2024.04.007 · Cited by 9
Yoyo Dieting, Post-Obesity Weight Loss, and Their Relationship with Gut Health
Phuong-Nguyen, K., McGee, S. L., Aston‐Mourney, K., McNeill, B. A., Mahmood, M. Q., & Rivera, L. R. (2024) · Nutrients · doi:10.3390/nu16183170 · Cited by 11
“To date, these medications are approved for long-term usage [130,131].”
BackgroundMoszak, M., Marcickiewicz, J., Pelczyńska, M., & Bogdański, P. (2025) · Nutrients · doi:10.3390/nu17101662 · Cited by 12
Obesity: assessment and treatment across the care continuum
Kushner, R. F., & Marla Shapiro, C. M. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2521433 · Cited by 14
“Generally, a patient is considered a ‘responder’ to an obesity medication if they lose ≥5% of their body weight within 3 months of starting a maintenance dose [26].”
InfluentialFeng, S., Wang, W., Zhang, X., Helal, S. E., Peng, N., & Zhang, Z. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1638771 · Cited by 11
Endoscopic Bypass Using Endobarrier Devices: Efficacy in Treating Obesity and Metabolic Syndrome
Jain, D., & Singhal, S. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000396 · Cited by 10
Strategies and methods for the correction of obesity and associated cardiovascular risk
Kuznetsova, Т. Y., Druzhilov, М. A., Chumakova, G. A., & Veselovskaya, N. G. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-4-61-67 · Cited by 11
Wu, W., Zhou, Q., Yuan, P., Qiao, D., Deng, S., Cheng, H., & Ren, Y. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s365192 · Cited by 12
“Lifestyle intervention and pharmacotherapy represent the most effective noninvasive weight loss approaches for the majority of obese patients.(34,35) Our data showed all three interventions effectively decreased body weight and were accompanied by improvements in metabolic variables.”
BackgroundTargeting Nanotechnology and Nutraceuticals in Obesity: An Updated Approach
Sharma, N., Behl, T., Singh, S., Kaur, P., Zahoor, I., Mohan, S., Rachamalla, M., Dailah, H. G., Almoshari, Y., Salawi, A., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666221003105619 · Cited by 11
HIV and obesity: updates in management strategies
Parra-Rodriguez, L., & O’Halloran, J. A. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000781 · Cited by 10
“Non HIV-specific guidelines recommend pharmacologic treatment for individuals with a BMI 30kg/m(2), or> 27kg/m(2) andweight-related comorbidities who have not achieved weight loss of at least 5%after 3–6monthswith lifestyle changes [43].”
BackgroundPharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis
Morsali, M., Poorolajal, J., Shahbazi, F., Vahidinia, A., & Doosti‐Irani, A. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.003 · Cited by 13
Economic Evaluations of Anti-obesity Interventions in Obese Adults: An Umbrella Review
Sharif, F. V., Yousefi, N., & Sharif, Z. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07104-9 · Cited by 10
Medical weight loss in older persons with obesity
Gavras, A., & Batsis, J. A. (2024) · Clinical Obesity · doi:10.1111/cob.12684 · Cited by 10
Fujioka, K., Sparre, T., Sun, L. Y.-H., Krogsgaard, S. M., & Kushner, R. F. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815593295 · Cited by 10
“Depending on BMI classification and the number/severity of comorbidities, behavioral therapy including dietary and physical activity changes, pharmacotherapy and (in the appropriate patient) bariatric surgery are recommended.(8,9) However, achieving and maintaining weight loss by diet and physical activity alone can b…”
BackgroundLahiri, S. W. (2017) · Clinical Diabetes · doi:10.2337/cd17-0083 · Cited by 11
Lifestyle and pharmacologic management before and after bariatric surgery
Moore, J. M., Haemer, M. A., & Fox, C. K. (2020) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2020.150889 · Cited by 13
Kapoor, E., Faubion, S. S., Hurt, R. T., Fischer, K. M., Schroeder, D. R., Fokken, S. C., & Croghan, I. T. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001599 · Cited by 10
“Lorcaserin was approved by the FDA in 2012 for weight management in individuals with a body mass index (BMI) of 27 kg/m(2) in the presence of at least one weightrelated condition such as type 2 diabetes, hypertension or dyslipidemia or in those with obesity (BMI 30 kg/m(2)).(22,23) LORCASERIN AND VA”
BackgroundRyan, D. H., Barquera, S., Cavalcanti, O. B., & Ralston, J. (2020) · Springer eBooks · doi:10.1007/978-3-030-05325-3_39-1 · Cited by 15
Self-citationMaia-Landim, A., Lancho, C., Poblador, M. S., Lancho, J. L., & Ramírez, J. M. (2021) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2021.100424 · Cited by 13
Choi, B. R., Yoon, D., Kim, H., Oh, S. M., Yoo, Y. C., Lee, Y., Kim, K.-W., Yi, T., & Lee, D. (2021) · Metabolites · doi:10.3390/metabo11080505 · Cited by 9
“Pharmacotherapy may help patients who find it difficult to begin physical activity and modify their lifestyle [8].”
BackgroundTsushima, Y., Zhou, K., Bena, J., & Kashyap, S. R. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.01.008 · Cited by 13
Diabetes in Native Populations and Underserved Communities in the USA
Joseph, J. J., & Golden, S. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-41559-8_14 · Cited by 9
CD1 is involved in diet-induced hypothalamic inflammation in obesity
Bombassaro, B., Ramalho, A. F. S., Fioravante, M., Solon, C., Nogueira, G. A. S., Nogueira, P. A. S., Gaspar, R. S., Ropelle, E. R., & Velloso, L. A. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.01.011 · Cited by 8
Gutman, R., Rauch, M., Neuman, A., Khamaisi, H., Jonas‐Levi, A., Konovalova, Y., & Rytwo, G. (2019) · Journal of Medicinal Food · doi:10.1089/jmf.2019.0030 · Cited by 9
“6 The only long-term effective over-the-counter oral medication for obesity is orlistat, which works by reducing breakdown and absorption of dietary triacylglycerol, thereby reducing energy absorption, 4,7,8 with an efficacy of up to 5% weight reduction.”
Hausmann, J., Wächtershäuser, A., Behnken, I., Aksan, A., Blumenstein, I., Brenner, M., Loitsch, S. M., & Stein, J. M. (2019) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2019.09.006 · Cited by 13
Medications Available for Weight Reduction in Elective Total Joint Arthroplasty
Amanatullah, D. F., Ohanisian, L. L., & Bailony, M. R. (2020) · JBJS Reviews · doi:10.2106/jbjs.rvw.19.00123 · Cited by 10
Weight Regain and Insufficient Weight Loss after Bariatric Surgery: A Call for Action
Elhag, W., & Ansari, W. E. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94848 · Cited by 10
“other WL medications were approved [83]: phentermine-topiramate, bupropion hydrochloride-naltrexone hydrochloride, liraglutide and lorcaserin hydrochloride (withdrawn due to cancer risk [84]).”
BackgroundWeight Management in Adults With Obesity: What Is a Primary Care Clinician to Do?
Yanovski, S. Z. (2018) · JAMA · doi:10.1001/jama.2018.11031 · Cited by 13
Rebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health
Singh, K., Aulakh, S. K., Nijjar, G. S., Singh, S., Sandhu, A. P. S., Luthra, S., Tanvir, F., Kaur, Y., Singla, A., & Kaur, M. S. (2024) · Cureus · doi:10.7759/cureus.64738 · Cited by 18
“Commonly prescribed medications for obesity include phentermine, orlistat, and newer agents like glucagon-like peptide-1 (GLP-1) agonists [14].”
BackgroundSmolińska, K., Hułas‐Stasiak, M., Dobrowolska, K., Sobczyński, J., Szopa, A., Tomaszewska, E., Muszyński, S., Smoliński, K., & Dobrowolski, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312723 · Cited by 11
Zinn, J., & Poretsky, L. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.12.001 · Cited by 10
Ostrominski, J. W., Wagholikar, K. B., Olsson, K., Ünlü, O., Zelle, D., Kumar, S., Smith, A. M., Toliver, J. C., Michalak, W., Fabricatore, A. N., et al. (2024) · Obesity · doi:10.1002/oby.24186 · Cited by 8
Self-citationYuan, Y. E., Haas, A. V., ROSNER, B. A., Williams, G. H., McDonnell, M. E., & Adler, G. K. (2025) · Obesity · doi:10.1002/oby.24218 · Cited by 10
Self-citationAlsuhibani, A. A., Alrasheed, M. A., Alhomoud, I. S., Alsahali, S. M., Almalki, Z. S., & Guo, J. J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1537181 · Cited by 11
Obesity Medication Treatment Perspectives Among People with Overweight or Obesity
Ostrominski, J. W., Chhibber, A., Kuti, E. L., Clark, B. J., & Donato, B. M. K. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s555622 · Cited by 8
Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Pendrey, A., & Sevilla‐Martir, J. (2025) · Obesity · doi:10.1002/oby.70029 · Cited by 11
Brill, J. V., Ashmore, J. A., Brengman, M. L., Buffington, D. E., Feldshon, S. D., Friedman, K. E., Margolis, P. S., Markus, D., Narramore, L., Rastogi, A., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.02.002 · Cited by 8
“Knowledgeable prescribing of medications with weight-reducing effects can aid in the prevention and management of obesity and thus improve health.(8) Incorporation of pharmacists into the multidisciplinary management program may assist with the pharmacologic management of obesity.”
Simon, J. A., Kingsberg, S. A., Goldstein, I., Kim, N. N., Hakim, B., & Millheiser, L. S. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.04.003 · Cited by 8
Moussa, S. A. A., Ibrahim, F. A. A., Elbaset, M. A., Aziz, S. W., Abdellatif, N., Attia, A. M., Toumy, S. A. E., Salib, J. Y., & Bashandy, S. A. E. (2022) · Journal of Applied Biology & Biotechnology · doi:10.7324/jabb.2022.100413 · Cited by 10
“There are various approaches to dealing with obese patients in treatment, such as nutritional system, sport and exercise medicine, abscission solution, lifestyle change, pharmacotherapy drug, acupuncture, and herbal medicine [16].”
Backgroundla Rosa, A. D., Ghusn, W., Sacoto, D., Campos, A., Cifuentes, L., Feris, F., Busebee, B. T., Calderón, G., Acosta, A. J., & Hurtado, M. D. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100046 · Cited by 8
“The use of anti-obesity medications (AOMs) is a reliable and ef fi ca-cious intervention for weight control, aiming at improving quality of life and preventing the progression of weight-related comorbidities [18,19].”
BackgroundResultObesity and Kidney Transplantation—How to Evaluate, What to Do, and Outcomes
Cocco, P. D., Bencini, G., Spaggiari, M., Petrochenkov, E., Akshelyan, S., Fratti, A., Zhang, J. C., Alvarez, J. A. A., Tzvetanov, I. G., & Benedetti, E. (2023) · Transplantation · doi:10.1097/tp.0000000000004564 · Cited by 9
Consensus on pharmacological treatment of obesity in Latin America
Cappelletti, A. M., Montero, A. V., Cercato, C., Ossman, J. J. D., Vasquez, P. E. F., García, J. E. G., Mancillas‐Adame, L. G., Manrique, H. A., Monterroso, F. D. M. R., Segarra, P., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13683 · Cited by 10
Hederagenin from Hedera helix Promotes Fat Browning in 3T3-L1 Adipocytes
Choi, S. M., Lee, H. S., Lim, S. H., Choi, G., & Choi, C. (2024) · Plants · doi:10.3390/plants13192789 · Cited by 10
“Additionally, obesity is associated with a higher incidence of cancer [3].”
BackgroundNutrient-Stimulating Hormone-Based Therapies for Obesity
Cristancho, C., Kim, D. W., & Apovian, C. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.006 · Cited by 8
Self-citationCutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options
Schmitz, S. H., Saunders, K. H., & Aronne, L. J. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.09.003 · Cited by 12
Self-citationManagement of childhood obesity
Kim, S.-H., & Park, M.-J. (2017) · Journal of Korean Medical Association · doi:10.5124/jkma.2017.60.3.233 · Cited by 9
Effectiveness of a dietary re-education and physical activity program on obesity
Christinelli, H. C. B., de Souza, J. M. S., Costa, M. A. R., Teston, É. F., Borim, M. L. C., & Fernandes, C. A. M. (2020) · Revista gaúcha de enfermagem · doi:10.1590/1983-1447.2020.20190213 · Cited by 8
“Isto é provocado devido ao excesso de ingestão realizado pelo individuo ao decorrer da vida de alimentos inadequados e esta manutenção dos maus hábitos alimentares proporciona um aumento progressivo do peso corporal(1,3).”
BackgroundLaughlin, M. R., Osganian, S. K., Yanovski, S. Z., & Lynch, C. J. (2021) · Obesity · doi:10.1002/oby.23079 · Cited by 12
“He noted that available drugs hit a variety of targets and although there are responders and nonresponders to all of them, they are far more successful when used successively or when combined in low doses (6,7).”
BackgroundGuideline for the evaluation of prescription appropriateness
Bian, J., Li, Q., Li, J., Yang, N., Zhang, W. Y., Mei, D., Zhong, M., Miao, L., Lu, X., Jiang, L., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7502 · Cited by 9
Kumar, R. B., & Aronne, L. J. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.010 · Cited by 12
Self-citationReal World Use of Anti-Obesity Medications and Weight Change in Veterans
Hung, A., Wong, E. S., Dennis, P. A., Stechuchak, K. M., Blalock, D. V., Smith, V. A., Hoerster, K. D., Vimalananda, V. G., Raffa, S. D., & Maciejewski, M. L. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08501-z · Cited by 11
Zhang, J.-Q., Xu, L. Z., & Mi, Y. (2015) · 国际内分泌与代谢研究 · doi:10.14725/gjems.v2n1.a1186 · Cited by 8
“Published by New Century Science Press 27 率。肥胖相关的代谢综合征如高血糖、高甘油三酯血症和高血压等严重影响人们的生活质量及健康,因此, 肥胖的治疗需得到重视。减轻体重是一种可以改善与肥胖相关的风险因素及肥胖合并症患者的健康的方法。 关于减肥的治疗方法有许多种,虽然以饮食、运动及行为干预治疗为主导的治疗方法对大部分患者疗效显 著。但有些患者却很难通过这种方式达到预期的减肥目的。2015 年美国内分泌学会制定的肥胖药物治疗指 南([1])提出在饮食、运动及行为干预治疗的基础上可行药物治疗。肥胖相关的药物治疗方法在 2002 年《肥胖 症的药物治疗与展望》及 2003 年《肥胖测量方法的评估及…”
ASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management
Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., Mergener, K., Dayyeh, B. A., Apovian, C. M., Burke, C. A., Chand, B., Chandraker, A. K., et al. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.08.004 · Cited by 9
“Multiple society guidelines provide a framework for learning about and treating obesity (American Association of Clinical Endocrinologists/American College of Endocrinology obesity guidelines 2016,(30) metabolic surgery guidelines 2016,(31) American College of Cardiology/American Heart Association/The Obesity Society…”
BackgroundSelf-citationBoutari, C., Pοlyzos, S. A., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.03.007 · Cited by 8
Caretto, A., Pintus, S., Petroni, M. L., Osella, A. R., Bonfiglio, C., Morabito, S., Zuliani, P., Sturda, A., Castronuovo, M., Lagattolla, V., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01100-8 · Cited by 12
Koh, Y. J., Lee, J., & Park, S. Y. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/4737515 · Cited by 10
“Obese patients who try losing weight via lifestyle interventions such as adjusting food intake and increasing the amount of physical exercise often fail to see significant improvements in their condition; moreover, pharmacotherapeutics aimed at managing obesity are often accompanied by side effects such as metabolic a…”
BackgroundThe diagnosis and evaluation of patients with obesity
Garvey, W. T. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.10.001 · Cited by 11
Dutta, N., Ingraham, N. E., Usher, M. G., Fox, C. K., Tignanelli, C. J., & Bramante, C. T. (2021) · Journal of Primary Care & Community Health · doi:10.1177/2150132721996283 · Cited by 9
Liao, Y.-N., Chen, H.-Y., Yang, C.-W., Lee, P.-W., Hsu, C.-Y., Huang, Y.-T., & Yang, T.-H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.978814 · Cited by 7
Han, B., Li, Z., Zhao, X.-Y., Liang, K., Mao, Y., Zhang, S., Huang, L., Kong, C., Peng, X., Chen, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53118-3 · Cited by 9
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Fu, Z., Zhou, S., & Gu, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1624982 · Cited by 8
“While this reduction may not meet the 5–10% threshold required for substantial cardiovascular risk reduction in obese patients (80), modest weight loss may still confer meaningful health benefits.”
Cerchi, E., Santo, P. A. D. E., de Oliveira, M. C., Janovsky, C. C. P. S., & Halpern, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01920-4 · Cited by 9
“Due to its multifactorial nature, a comprehensive therapeutic approach is recommended, encompassing lifestyle modi fi cations and, optionally, pharmacological treatment to assist in weight loss and its long-term maintenance [3, 4].”
Physiology of the Weight-Reduced State and Its Impact on Weight Regain
Hafida, S., & Apovian, C. M. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.06.002 · Cited by 8
Self-citationClassification, Diagnosis, and Treatment of Obesity-Related Heart Diseases
Chen, D., Feng, J., He, H., Xiao, W., & Liu, X. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0134 · Cited by 12
“60 Work by Neeland et al. has shown that 3.0 mg/day of liraglutide can reduce visceral fat among adults who are overweight or obese and at a high risk of CV disease but do not have type 2 diabetes mellitus, and visceral fat is the core element of the pathogenesis of the CV disease.”
InfluentialEffective and appropriate use of weight loss medication in pediatric obesity: a narrative review
Chung, L. Y. (2024) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2024.00353 · Cited by 8
“Discontinuation of AOM is recommended if 5% weight loss/BMI reduction from baseline is achieved within 12 weeks at the maximum appropriate dose [11,16,17].”
BackgroundPark, Y. W., Choi, K. B., Kim, S. K., Lee, D., & Lee, J. H. (2016) · The World Journal of Men s Health · doi:10.5534/wjmh.2016.34.2.129 · Cited by 7
“Additionally, obesity requiring pharmacotherapy was defined as the presence of a BMI ≥30 kg/m(2) or the co-occurrence of a BMI ≥ 27 kg/m(2) with at least one associated comorbid medical condition, such as hypertension, dyslipidemia, diabetes, or obstructive sleep apnea [6].”
BackgroundMethodInfluentialCardiometabolic Effects of Anti-obesity Pharmacotherapy
Crawford, A. R., Alamuddin, N., & Amaro, A. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0719-9 · Cited by 10
Farmakoterapia otyłości — obecny stan wiedzy
Matyjaszek‐Matuszek, B., Szafraniec, A., & Porada, D. (2018) · Endokrynologia Polska · doi:10.5603/ep.2018.0048 · Cited by 13
McCarty, T. R., Sharma, P., Lange, A., Ngu, J. N., Davis, A. C., & Njei, B. M. (2020) · Bariatric Surgical Practice and Patient Care · doi:10.1089/bari.2019.0065 · Cited by 9
“Pharmacotherapy for obesity has led to modest reduction in excess weight, with substantial side effects.(20) Bariatric surgery, on the other hand, has been shown to be a safe and effective treatment modality for obese individuals.”
BackgroundModesto, A. C. F., Silveira, É. A., Santos, A. S. E. A. D. C., Rodrigues, A. P. D. S., Lima, D. M., Provin, M. P., & Amaral, R. G. (2020) · Scientia Pharmaceutica · doi:10.3390/scipharm88040041 · Cited by 7
Bukhari, H. M., Zahran, S. E., Bakr, E.-S. H., Sahibzadah, F. A., & Header, E. A. (2021) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2021.165165 · Cited by 8
“That same year, in response to occasional reports of severe liver injury using the weight-loss drug xenical, the Food and Drug Administration (FDA) approved a revised drug label in which safety information about its potential side effects was noted ((29)).”
BackgroundChen, W.-Y., Chen, Y., Ke, C., Chen, C., & Lin, F. (2021) · Materials · doi:10.3390/ma14164467 · Cited by 8
“These include the lipase inhibitors (Roche, Materials 2021, 14, 4467. https://doi.org/10.3390/ma14164467 https://www.mdpi.com/journal/materials Materials 2021, 14, 4467 2 of 11 Basel, Switzerland, Orlistat, Xenical®), serotonin agonists (Arena Pharmaceuticals, San Diego, CA, USA, Lorcaserin, Belviq®), combination of p…”
InfluentialPerceptions of obesity pharmacotherapy by nurse practitioners
Bottcher, K., & Chao, A. M. (2021) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000678 · Cited by 8
“Guidelines recommend that these treatments are provided in a stepwise approach based on increasing BMI as well as obesity-related comorbidities (Apovian et al., 2015; Jensen et al., 2014).”
BackgroundBlüher, M., & Stümvoll, M. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_1 · Cited by 13
An algorithm for the use of anti-obesity medications
Dehghani, F., Ahmadi, M., Hefner, M., Kudchadkar, G., Najam, W., Nateqi, M., Siddik, M. A. B., Booe, H. L., & Dhurandhar, N. V. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00278-2 · Cited by 7
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.